SUNNYVALE, Calif. (BUSINESS WIRE) May 31, 2006 Intraop Medical Corporation (OTCBB: IOPM) has received two orders from Japan for its proprietary Mobetron® system, a mobile electron-beam device designed for intraoperative radiation therapy (IORT). The new Mobetrons will be installed at the Gunma Prefectural Cancer Center and Nagoya University Hospital, two treatment locations already actively administering IORT, the direct application of radiation to a tumor while a patient is undergoing cancer surgery. With these two orders, Intraop has sold 17 Mobetron units worldwide, including three in Japan.

"These two orders, our 16th and 17th worldwide, and our second and third in Japan, follow the recent sale of a to Saint Augustinius Hospital in Antwerp, Belgium. We believe this is a result of a successful business development program, which we hope will continue to increase sales," said Dr. Donald A. Goer, President and Chief Executive Officer of Intraop. "We have been working diligently with our partner in Japan, Chiyoda Technol Corporation, to introduce the Mobetron's modern IORT technology to Japan, and we are gratified that these efforts are beginning to bear fruit. The Mobetron allows treatments to be delivered with greater convenience and less cost and disruption, and we believe other hospitals in Japan are likely to follow the example of Nagoya and Gunma."

Gunma Prefectural Cancer Center and Nagoya University Hospital are two of 80 hospitals in Japan with active IORT programs. Although Japan is considered the birthplace of modern IORT, almost all Japanese centers transport the patient, in the midst of surgery, from the operating room to the radiation department to receive the IORT treatment. The Mobetron, by contrast, is self-shielded and designed for use in the operating room. The Gunma and Nagoya Mobetron units will be the first IORT systems in the country to be located in the OR.

The hospitals intend to focus initially on the use of IORT for pancreatic cancer and early-stage breast cancer. Nagoya has requested delivery of its Mobetron this year. Gunma has asked for delivery of its Mobetron to coincide with the opening of its new cancer center hospital in early 2007.

About Gunma Prefectural Cancer Center and Nagoya University Hospital

With a population of 2,032,709, Gunma, located northwest of Tokyo, is the 19th most populous of Japan's 47 prefectures. Gunma Prefectural Cancer Center is the main cancer treatment center for the prefecture. The Mobetron will be delivered to Gunma in early 2007 to coincide with the completion of its new cancer hospital.

Nagoya, Japan's fourth largest city and the capital of Aichi prefecture, is located southwest of Tokyo. The Mobetron at Nagoya University, one of the major cancer treatment centers in the prefecture, is scheduled to begin clinical treatment before the end of the year.

About Intraop

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intraoperative radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

Forward-looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.